Molecular Target Synopsis
Overview
Domains and Structures
Drugs and Clinical Candidates
Druggability
Chemistry
Ligand Efficiency Plot
Pathways
Family Cladogram
Interaction Network
Gene Expression
Gene Copy Number Variation
RNAi
Mutations
Germline Genetics

PIM2 (Q9P1W9) - Overview - Molecular Target Synopsis

Protein


PIM2, Serine/threonine-protein kinase pim-2
Enzyme Classification 2.7.11.1
UniProt Q9P1W9

Also Known as PIM2_HUMAN, PIM2

Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression, the regulation of cap-dependent protein translation and through survival signaling by phosphorylation of a pro-apoptotic protein, BAD. Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase transcriptional activity. The stabilization of MYC exerted by PIM2 might explain partly the strong synergism between these 2 oncogenes in tumorigenesis. Regulates cap-dependent protein translation in a mammalian target of rapamycin complex 1 (mTORC1)-independent manner and in parallel to the PI3K-Akt pathway. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Promotes cell survival in response to a variety of proliferative signals via positive regulation of the I-kappa-B kinase/NF-kappa-B cascade; this process requires phosphorylation of MAP3K8/COT. Promotes growth factor-independent proliferation by phosphorylation of cell cycle factors such as CDKN1A and CDKN1B. Involved in the positive regulation of chondrocyte survival and autophagy in the epiphyseal growth plate. Interacts with MYC.

4X7Q
PIM2 KINASE IN COMPLEX WITH COMPOUND 1S
RCSB/PDB
Inspect Structure
See all 3D Structures for PIM2

Isoforms / Transcripts (Protein Coding)


Protein Length Ensembl Gene Ensembl Transcript Ensembl Protein Uniprot Isoform
311ENSG00000102096ENST00000376509ENSP00000365692Q9P1W9-1
145ENSG00000102096ENST00000442430ENSP00000410960

Sub-cellular localization


GO terms: PIM2 is active in the following subcellular-locations: cytoplasm.



UniProt
GO terms

Gene Copy Number Variation


In COSMIC - Cell Lines Project PIM2 has gain in 1 cell-lines, loss in 61 cell-lines and no signal in 943 cell-lines. (see details)

Gene Expression


In NCI60, the highest expressing cell lines are: RPMI_8226, K_562, BT_549

In Array Express (RNA-seq of 675 commonly used human cancer cell lines), the highest expressing cell lines are: KMS-34, NCI-H929, KMS-26

In Array Express (RNA-seq of long poly adenylated RNA and long non poly adenylated RNA from ENCODE cell lines), the highest expressing cell lines are: K562, SK-N-SH, CD20-positive B cell

(see details)

RNA Interference


PIM2 was reported in the following RNAI studies:

Cell - Large Scale Profiling of Kinase Dependencies in Cancer Cell Lines, the highest RNAi cell lines are: SKGT4, H358. (see details)

3D Structures


For PIM2 there are:
2 structures (4 chains) solved
2 are solved in complex with at least one small molecule ligand



(see details)
Molecular Target 3D Synopsis

Screening and Chemistry


PIM2 has been screened with 2695 compounds (3803 bioactivities), 1193 compounds have bioactivities that show binding affinity of <= 500nM (1356 bioactivities). (see details)